Seelos Therapeutics, Inc. financial data

Symbol
SEEL on Nasdaq
Industry
Pharmaceutical Preparations
Location
300 Park Avenue, 2 Nd Floor, New York, NY
State of incorporation
Nevada
Fiscal year end
December 31
Former names
APRICUS BIOSCIENCES, INC. (to 1/24/2019), NEXMED INC (to 9/13/2010)
Latest financial report
10-Q - Q2 2024 - Aug 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 12.4 % -82.2%
Debt-to-equity -114 % +52.5%
Return On Equity -13.1 % -103%
Return On Assets 92.8 %
Operating Margin -1.48K %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 5.96M shares -95.3%
Common Stock, Shares, Outstanding 3.32M shares -97.3%
Entity Public Float 145M USD
Common Stock, Value, Issued 3K USD -97.6%
Weighted Average Number of Shares Outstanding, Basic 2.51M shares +356%
Weighted Average Number of Shares Outstanding, Diluted 2.52M shares +358%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 2.01M USD +11.9%
Research and Development Expense 20.4M USD -54%
General and Administrative Expense 11.4M USD -7.12%
Operating Income (Loss) -29.8M USD +46.3%
Nonoperating Income (Expense) 33.9M USD
Net Income (Loss) Attributable to Parent 4.09M USD
Earnings Per Share, Basic 50 USD/shares
Earnings Per Share, Diluted 49.4 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 30.5M USD -60.3%
Accounts Receivable, after Allowance for Credit Loss, Current 188K USD -56.4%
Assets, Current 2.33M USD -80.3%
Operating Lease, Right-of-Use Asset 47K USD +6.82%
Assets 2.38M USD -80%
Accounts Payable, Current 15.7M USD +144%
Employee-related Liabilities, Current 471K USD -38.3%
Accrued Liabilities, Current 4.36M USD -22%
Liabilities, Current 30.5M USD -45.6%
Operating Lease, Liability, Noncurrent 15K USD
Liabilities 30.5M USD -48.3%
Retained Earnings (Accumulated Deficit) -254M USD +1.59%
Stockholders' Equity Attributable to Parent -28.1M USD +40.4%
Liabilities and Equity 2.38M USD -80%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.64M USD +55.1%
Net Cash Provided by (Used in) Financing Activities 2.17M USD -75.5%
Common Stock, Shares Authorized 50M shares -89.6%
Common Stock, Shares, Issued 3.32M shares -97.3%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -2.47M USD -67.7%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 294K USD -95%
Interest Paid, Excluding Capitalized Interest, Operating Activities 180K USD +57.9%
Deferred Tax Assets, Valuation Allowance 56M USD +14%
Deferred Tax Assets, Gross 56M USD +14%
Operating Lease, Liability 47K USD +2.17%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -19.6M USD -81.3%
Lessee, Operating Lease, Liability, to be Paid 48K USD 0%
Operating Lease, Liability, Current 47K USD +2.17%
Lessee, Operating Lease, Liability, to be Paid, Year Two 16K USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year One 32K USD 0%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure -99%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1K USD -50%
Deferred Tax Assets, Operating Loss Carryforwards 33.2M USD +21.3%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Preferred Stock, Shares Outstanding 0 shares
Interest Expense 91K USD +550%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%